Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 23;8(2):e001620. doi: 10.1136/jitc-2020-001620

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Effect of HLA-I/II homozygosity on OS and PFS in patients with NSCLC treated with anti-PD1/PD-L1 immunotherapy. A and B, comparison of patients with homozygosity at one or more HLA-I loci on OS and PFS, respectively. C and D, comparison of patients with homozygosity at one or more HLA-II loci on OS and PFS, respectively. Kaplan-Meier curves were compared using log-rank analysis. HLA, human leukocyte antigen; NSCLC, non-small cell lung cancer; OS, overallsurvival; PD1/PDL1, programmed cell death protein-1/programmed death ligand 1; PFS, progression free survival.